ArticleJournal of the Chinese Medical Association : JCMA2025
Elevated CCL20 expression was associated with poor prognosis for breast cancer.
Article in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers.Breast cancer research : BCR · 2026Article
- Management of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer patients: First-line therapy.Journal of the Chinese Medical Association : JCMA · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe chemokine (C-C motif) ligand 20 (CCL20) exhibits pronounced expression within tumor cells, effectively facilitating tumor progression by modulating the immunosuppressive microenvironment and promoting tumor cell aggressiveness.
methodsBreast cancer and matched adjacent normal tissues from 113 adult breast cancer patients were collected for immunohistochemical staining of CCL20, E-cadherin, vimentin, and N-cadherin. The assessment evaluated the association between CCL20 expression and clinicopathological factors using Pearson chi-squared test, epithelial-mesenchymal transition (EMT) markers expression using Spearman's rank correlation test, both OS and DFS using Kaplan-Meier survival analysis, and Cox proportional hazards regression modeling.
resultsCytoplasmic CCL20 expression was stronger in cancer tissues, compared to normal tissue (69.9% vs 23%). Strong correlations were observed between CCL20 expression and many clinicopathological features, including tumor size ( p = 0.000), estrogen receptor (ER) status ( p = 0.003), Ki67 status ( p = 0.000), vascular invasion ( p = 0.001), and tumor-node-metastasis stage ( p = 0.001). Additionally, CCL20 expression was an independent prognostic predictor for overall survival (OS) (hazard ratio [HR], 3.207; 95% CI, 1.142-9.005, p = 0.027). Furthermore, a significant association between CCL20 expression and EMT markers was observed. CCL20 expression was linked to unfavorable outcomes in all patients ( p = 0.000), ER-positive patients ( p = 0.001), and node-positive/negative ( p = 0.005/0.001) subgroups.
conclusionThese findings highlighted that elevated CCL20 expression was linked to a more aggressive tumor phenotype and a disappointing OS in breast cancer patients, thus advocating for the consideration of CCL20 expression being a novel independent prognostic biomarker for guiding bespoke treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.